Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Share Capital (Tables)

v3.23.1
Share Capital (Tables)
 12 Months Ended
Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]  
Schedule of stock option activities and related information
    Number of ordinary
shares		     Number of ordinary
shares		  
    Authorized     Issued and
outstanding		     Authorized     Issued and
outstanding		  
    December 31, 2022     December 31, 2021  
                                 
Ordinary shares     1,200,000,000       147,134,792       1,200,000,000       90,205,191  

 
Schedule of options granted outstanding and exercise prices
    Number of
options		     Weighted
average
exercise
price		     Weighted
average
remaining
contractual
life (years)		     Aggregate
intrinsic-
value		  
                         
Outstanding as of January 1, 2021     18,323,222     $ 0.12                  
Granted*     6,600,000       0.07                  
Forfeited     (2,655,464 )     0.10                  
                                 
Outstanding as of December 31, 2021     22,267,758     $ 0.11       4.66     $
—
  
                                 
Exercisable as of December 31, 2021     15,999,078     $ 0.12       4.00     $
    —
  

 

*

1,249,758 options approved for grant to the Company’s new Chief Executive Officer were not issued since the number of reserved shares under the Company’s 2010 Option Plan was not sufficient to support such grant in its totality (and therefore not presented within the Granted line item above). See Note 13.e. for additional information.

 

    Number of
options		     Weighted
average
exercise
price		     Weighted
average
remaining
contractual
life (years)		     Aggregate
intrinsic-
value		  
                         
Outstanding as of January 1, 2021     16,319,786     $ 0.12                  
Granted     2,003,436       0.17                  
                                 
Outstanding as of December 31, 2021     18,323,222     $ 0.12       4.97     $ 342,452  
                                 
Exercisable as of December 31, 2021     11,332,153     $ 0.08       4.68     $ 233,086  

 
Schedule of options granted to officers, directors, employees, consultants and service providers
      Outstanding     Exercisable  
Exercise price     Number of
options		     Weighted average
remaining
contractual life
(years)		     Number of
options		     Weighted average
remaining
contractual life
(years)		  
                           
$ 0.03       4,451       1.8       4,451       1.8  
  0.068       13,728,037       4.0       13,649,773       4.0  
  0.07       5,300,000 (*)     6.5      
—
      
—
  
  0.17       2,003,436       5.4       1,113,020       5.4  
  0.27       739,000       3.0       739,000       3.0  
  0.34       8,020       0.9       8,020       0.9  
  0.92       455,501       1.5       455,501       1.5  
$ 5.73       29,313       0.9       29,313       0.9  
          22,267,758               15,999,078          

 

  *

1,249,758 options approved for grant to the Company’s new Chief Executive Officer were not issued since the number of reserved shares under the Company’s 2010 Option Plan was not sufficient to support such grant in its totality (and therefore not presented within the related line item above). See Note 13.e. for additional information.

 

      Outstanding     Exercisable  
Exercise price     Number of
options		     Weighted average
remaining
contractual life
(years)		     Number of
options		     Weighted average
remaining
contractual life
(years)		  
                           
  (* )     230,425       —       230,425       —  
$ 0.03       19,288       2.8       19,288       2.8  
  0.068       14,678,734       5.0       9.507,559       5.0  
  0.17       2,003,436       6.4       —       —  
  0.27       809,000       4.0       792,542       4.0  
  0.34       8,020       1.9       8,020       1.9  
  0.92       540,501       2.4       540,501       2.4  
  4.72       1,068       0.2       1,068       0.2  
  5.05       2,769       0.2       2,769       0.2  
$ 5.73       29,981       1.8       29,981       1.8  
          18,323,222               11,332,153          

 

(*) Represents an amount lower than $0.01.

 
Schedule of stock based compensation
    Year Ended December 31,  
    2022     2021     2020  
                   
Research and Development   $ 130,637     $ 147,696     $ 167,328  
Sales and Marketing     30,804       47,031       48,671  
General and Administrative     319,501       263,646       248,774  
                         
    $ 480,942     $ 458,373     $ 464,773  

 
Schedule of outstanding warrants
Outstanding     Issuance
year		     Exercise
price		     Exercisable through      
                         
  117,209       2009     $                (* )     Exit event     (**)
  59,384       2013       0.92       2023     (**)
  170,000       2018       0.50       2023     See Note 8.b.
  200,001       2018       0.50       2023     (**)
  27,857,140       2022     $ 0.07       2024(***)     See Note 11.b.9 and 17
                                 
  28,403,734                              

 

Outstanding     Issuance
year		     Exercise
price		     Exercisable through      
                         
  117,209       2009     $                (* )     Exit event     (**)
  59,384       2013       0.92       2023     (**)
  170,000       2018       0.50       2023     See Note 8.b.
  200,001       2018     $ 0.50       2023     (**)
                                 
  546,594